HopeStage
Back to all studies
CompletedNCT00314821

Ropinirole for depression in bipolarity

About this title

Ropinirole in the Treatment of Bipolar Depression

Read the official source — NCT00314821
Medication studyAges 18–64United States
The study in practice

Understand this study

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Listed locations
Atlanta and 1 more locationSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 2005
Recruitment status
Completed
Enrollment listed in the registry
40
Sponsor
Cambridge Health Alliance
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 64 Years
Official registry ID
NCT00314821
Official title
Show the full official title

A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Atlanta · Cambridge

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Cambridge Health Alliance.

Did this study involve medication?

Yes. The study involved medication, including ropinirole.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies